

Pierre Laurent-Puig

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1665250/pierre-laurent-puig-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

406
papers

41,918
citations

87
h-index

200
g-index

488
ext. papers

48,582
ext. citations

7.4
avg, IF

6.62
L-index

#	Paper	IF	Citations
406	Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma.. <i>Clinical Chemistry</i> , 2022 ,	5.5	1
405	BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022 , 101880	2.4	
404	Translational epigenetics in precision medicine of colorectal cancer 2022 , 19-41		
403	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.. <i>Immunity</i> , 2022 ,	32.3	11
402	Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. <i>Modern Pathology</i> , 2021 ,	9.8	2
401	Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. <i>BMC Cancer</i> , 2021 , 21, 1180	4.8	2
400	Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. <i>Cell Death and Disease</i> , 2021 , 12, 978	9.8	1
399	The Cellular Prion Protein and the Hallmarks of Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
398	Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. <i>British Journal of Cancer</i> , 2021 , 125, 1544-1551	8.7	2
397	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). <i>European Journal of Cancer</i> , 2021 , 159, 24-33	7.5	2
396	Highly Sensitive Quantification of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its Potential Clinical Value. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2890-e2897	11.6	63
395	Facing new challenges to informed consent processes in the context of translational research: the case in CARPEM consortium. <i>BMC Medical Ethics</i> , 2021 , 22, 21	2.9	1
394	Gene network and biological pathways associated with susceptibility to differentiated thyroid carcinoma. <i>Scientific Reports</i> , 2021 , 11, 8932	4.9	1
393	Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case-Control Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1208-1217	4	1
392	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab □ Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021 , 53, 420-426	3.3	4
391	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101681	2.4	
390	Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays. <i>Frontiers in Oncology</i> , 2021 , 11, 639675	5.3	1

389	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 5638-5646	12.9	11
388	Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study). <i>BMC Cancer</i> , 2021 , 21, 711	4.8	0
387	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4768-4780	12.9	5
386	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021 , 11, 408-423	24.4	12
385	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021 , 144, 101-112	7.5	4
384	Prognostic value of the PrP-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. <i>Oncolmmunology</i> , 2021 , 10, 1940674	7.2	4
383	Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient. <i>Stem Cell Reviews and Reports</i> , 2021 , 17, 296-299	7.3	7
382	Multiethnic genome-wide association study of differentiated thyroid cancer in the EPITHYR consortium. <i>International Journal of Cancer</i> , 2021 , 148, 2935-2946	7.5	5
381	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021 , 53, 318-323	3.3	4
380	Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 2q35 and 8p12 in Europeans, Melanesians and Polynesians. <i>Oncotarget</i> , 2021 , 12, 493-506	3.3	2
379	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy. <i>Cancer Research</i> , 2021 , 81, 2730-2744	10.1	1
378	Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). <i>Lung Cancer</i> , 2021 , 157, 124-130	5.9	2
377	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. <i>Lancet Oncology, The</i> , 2021 , 22, 1014-1022	21.7	5
376	Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. <i>Clinical Cancer Research</i> , 2021 , 27, 6491-6499	12.9	1
375	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , 2021 , 13,	6.6	3
374	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021 , 53, 1254-1259	3.3	2
373	Circulating ubiquitous RNA, a highly predictive and prognostic biomarker in hospitalized COVID-19 patients. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	1
372	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020 , 52, 572-581	36.3	76

371	Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. <i>Genetics in Medicine</i> , 2020 , 22, 1533-1541	8.1	9
370	Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the EPICAP study. <i>International Journal of Cancer</i> , 2020 , 147, 3119-3129	7.5	7
369	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
368	Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5208-5216	12.9	12
367	Biochemically Tracked Variability of Blood Plasma Thawed-State Exposure Times in a Multisite Collection Study. <i>Biopreservation and Biobanking</i> , 2020 , 18, 376-388	2.1	0
366	The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection. <i>Biometrical Journal</i> , 2020 , 62, 1476-1493	1.5	2
365	Role of GSTM1 and GSTT1 genotypes in differentiated thyroid cancer and interaction with lifestyle factors: Results from case-control studies in France and New Caledonia. <i>PLoS ONE</i> , 2020 , 15, e0228187	3.7	2
364	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. <i>Cancer Treatment Reviews</i> , 2020 , 87, 102028	14.4	5
363	Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2020 , 147, 1185-1189	7.5	14
362	Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. <i>Digestive and Liver Disease</i> , 2020 , 52, 347-350	3.3	1
361	HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers. <i>International Journal of Cancer</i> , 2020 , 147, 1222-1227	7.5	26
360	Effectiveness of a dedicated small bowel neoplasia screening program by capsule endoscopy in Lynch syndrome: 5 years results from a tertiary care center. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820934314	4.7	1
359	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRODIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , 2020 , 52, 1143-1147	3.3	2
358	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020 , 31, 1291-1305	10.3	165
357	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2020 , 10,	5.9	22
356	YAP/TAZ Signalling in Colorectal Cancer: Lessons from Consensus Molecular Subtypes. <i>Cancers</i> , 2020 , 12,	6.6	5
355	Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives. <i>Cancer Cytopathology</i> , 2020 , 128, 601-610	3.9	5
354	Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. <i>Trials</i> , 2020 , 21, 764	2.8	2

353	The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions. <i>OncImmunology</i> , 2020 , 9, 1812221	7.2	5
352	Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. <i>Journal of Medical Genetics</i> , 2020 , 57, 104-108	5.8	10
351	Circadian genes and risk of prostate cancer: Findings from the EPICAP study. <i>International Journal of Cancer</i> , 2019 , 145, 1745-1753	7.5	8
350	NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas. <i>Cancer Medicine</i> , 2019 , 8, 4330-4337	4.8	4
349	Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. <i>International Journal of Cancer</i> , 2019 , 145, 3163-3172	7.5	6
348	A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. <i>JCO Clinical Cancer Informatics</i> , 2019 , 3, 1-17	5.2	1
347	Successful Targeting of an ATG7-RAF1 Gene Fusion in Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal Dissemination.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-7	3.6	2
346	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. <i>British Journal of Cancer</i> , 2019 , 120, 697-702	8.7	9
345	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 844-856	8.9	27
344	DNAsell Protects DNA Stored at Room Temperature for Downstream Next-Generation Sequencing Studies. <i>Biopreservation and Biobanking</i> , 2019 , 17, 352-354	2.1	1
343	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2019 , 112, 1-8	7.5	16
342	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 134-141	12.9	28
341	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019 , 46, 94-104	8.8	17
340	Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , 2019 , 11,	6.6	11
339	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019 , 79, 1375-1394	12.1	29
338	Molecular targeted therapy of -mutant colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919856494	5.4	54
337	Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4136-4136	2.2	2
336	Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. <i>Journal of Thoracic Disease</i> , 2019 , 11, S25-S36	2.6	31

335	Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2019 , 9, 16971	4.9	25
334	hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. <i>Cancers</i> , 2019 , 11,	6.6	11
333	Systemic treatment of pancreatic cancer revisited. <i>Seminars in Oncology</i> , 2019 , 46, 28-38	5.5	48
332	Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: A gene-set analysis. <i>International Journal of Cancer</i> , 2019 , 144, 1896-1908	7.5	8
331	Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. <i>Pathology and Oncology Research</i> , 2019 , 25, 319-325	2.6	2
330	Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e369-e379	3.8	30
329	BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μ and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA. <i>Analytical Chemistry</i> , 2018 , 90, 3766-3774	7.8	25
328	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). <i>Digestive and Liver Disease</i> , 2018 , 50, 408-410	3.3	8
327	Are There Biochemical and Molecular Biological Factors to Distinguish the Rectal Cancer by the Colon Cancer? 2018 , 503-507		
326	Role of circulating tumor DNA in the management of patients with colorectal cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018 , 42, 396-402	2.4	11
325	Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation. <i>Genetics in Medicine</i> , 2018 , 20, 1589-1599	8.1	13
324	RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. <i>Annals of Oncology</i> , 2018 , 29, 1211-1219	10.3	84
323	RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014. <i>Digestive and Liver Disease</i> , 2018 , 50, 507-512	3.3	10
322	Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine. <i>Science and Engineering Ethics</i> , 2018 , 24, 307-322	3.1	19
321	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	64
320	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 379-383	13.4	64
319	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2018 , 24, 4745-4753	12.9	14
318	Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	41

317	Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma. <i>Neurology</i> , 2018 , 91, 523-525	6.5	14
316	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. <i>BMC Cancer</i> , 2018 , 18, 828	4.8	15
315	Increased expression of the thyroid hormone nuclear receptor TR β 1 characterizes intestinal tumors with high Wnt activity. <i>Oncotarget</i> , 2018 , 9, 30979-30996	3.3	6
314	Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 7-17	3.8	102
313	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <i>JAMA Oncology</i> , 2018 , 4, e173695	13.4	37
312	-Activating Mutations in Small Bowel Adenocarcinomas.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-9	3.6	1
311	Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, E23-E27	2.8	6
310	Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. <i>Gastroenterology</i> , 2018 , 155, 1999-2013.e3	13.3	189
309	, and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5710-5723	12.9	150
308	Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 550-564	5.1	17
307	Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. AuthorsReply. <i>Digestive and Liver Disease</i> , 2018 , 50, 974-975	3.3	
306	Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. <i>Journal of Pathology</i> , 2017 , 242, 10-15	9.4	89
305	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <i>Onc Immunology</i> , 2017 , 6, e1286437	7.3	21
304	BCL-2 system analysis identifies high-risk colorectal cancer patients. <i>Gut</i> , 2017 , 66, 2141-2148	19.2	27
303	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. <i>Annals of Oncology</i> , 2017 , 28, 958-968	10.3	53
302	Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank. <i>BMC Public Health</i> , 2017 , 17, 324	4.1	4
301	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2017 , 79, 41-49	7.5	36
300	Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. <i>Annals of Oncology</i> , 2017 , 28, 1597-1604	10.3	22

299	Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 953-960	3.5	29
298	Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma. <i>Targeted Oncology</i> , 2017 , 12, 365-371	5	12
297	CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. <i>Annals of Oncology</i> , 2017 , 28, 1032-1035	10.3	32
296	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 562-576	19.4	102
295	Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. <i>Annals of Oncology</i> , 2017 , 28, 824-830	10.3	31
294	Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. <i>Clinical Cancer Research</i> , 2017 , 23, 116-123	12.9	155
293	A comprehensive characterization of the impact of mycophenolic acid on the metabolism of Jurkat T cells. <i>Scientific Reports</i> , 2017 , 7, 10550	4.9	12
292	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017 , 82, 16-24	7.5	28
291	Partnering with patients in translational oncology research: ethical approach. <i>Journal of Translational Medicine</i> , 2017 , 15, 74	8.5	7
290	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). <i>Clinical Cancer Research</i> , 2017 , 23, 5416-5425	12.9	129
289	Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 678-690	12.7	11
288	Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. <i>American Journal of Transplantation</i> , 2017 , 17, 1008-1019	8.7	10
287	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1200-1212	12.9	14
286	Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. <i>Cancers</i> , 2017 , 9,	6.6	42
285	Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3509-3509	2.2	23
284	6-mercaptopurine promotes energetic failure in proliferating T cells. <i>Oncotarget</i> , 2017 , 8, 43048-43060	3.3	12
283	Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. <i>Oncotarget</i> , 2017 , 8, 93856-93866	3.3	31
282	Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 23831-23840	3.3	42

281	Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. <i>European Journal of Human Genetics</i> , 2016 , 24, 99-105	5.3	14
280	Angiogenin Mediates Cell-Autonomous Translational Control under Endoplasmic Reticulum Stress and Attenuates Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 863-76	12.7	24
279	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
278	Women at a Disadvantage in Fluorouracil Treatment-Reply. <i>JAMA Oncology</i> , 2016 , 2, 830-1	13.4	
277	Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 9q22.33 and 14q13.3 detects novel candidate functional SNPs in Europeans from metropolitan France and Melanesians from New Caledonia. <i>International Journal of Cancer</i> , 2016 , 139, 617-27	7.5	9
276	A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker. <i>Clinical Chemistry</i> , 2016 , 62, 1129-39	5.5	85
275	Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 1403-1412	10.2	34
274	DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 655-662	13.4	37
273	Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. <i>JAMA Oncology</i> , 2016 , 2, 643-653	13.4	87
272	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , 2016 , 44, 698-711	32.3	602
271	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 4057-66	12.9	306
270	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016 , 130, 95-190	5.6	120
269	Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 154-60	2.4	27
268	A Novel Extrinsic Pathway for the Unfolded Protein Response in the Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 2670-83	12.7	21
267	Methylator phenotype in colorectal cancer: A prognostic factor or not?. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 74-80	7	35
266	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 205-14	5.1	18
265	Proof of Principle for Mutations Monitoring Using Picoliter-Droplet Digital PCR on DNA and Living Cells: Application to Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 5515-5515	2.2	
264	Integrating Heterogeneous Biomedical Data for Cancer Research: the CARPEM infrastructure. <i>Applied Clinical Informatics</i> , 2016 , 7, 260-74	3.1	22

263	Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations. <i>PLoS ONE</i> , 2016 , 11, e0159094	3.7	64
262	Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. <i>PLoS Medicine</i> , 2016 , 13, e1002199	11.6	58
261	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422	10.3	1683
260	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016 , 17, 218	18.3	791
259	Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. <i>Clinical Chemistry</i> , 2016 , 62, 1492-1503	5.5	54
258	Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. <i>British Journal of Cancer</i> , 2015 , 113, 680-5	8.7	10
257	Frequent intragenic rearrangements of DPYD in colorectal tumours. <i>Pharmacogenomics Journal</i> , 2015 , 15, 211-8	3.5	3
256	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. <i>BMC Cancer</i> , 2015 , 15, 26	4.8	42
255	STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. <i>BMC Cancer</i> , 2015 , 15, 496	4.8	17
254	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015 , 350, 972-973	33.3	267
253	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , 2015 , 21, 1350-6	50.5	2332
252	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. <i>Clinical Cancer Research</i> , 2015 , 21, 1087-97	12.9	122
251	PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. <i>Cancer Medicine</i> , 2015 , 4, 371-82	4.8	20
250	Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 2436-43	4.6	12
249	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>OncImmunology</i> , 2015 , 4, e1049804	7.2	34
248	Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. <i>Cancer Treatment Reviews</i> , 2015 , 41, 129-35	14.4	14
247	Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study. <i>American Journal of Gastroenterology</i> , 2015 , 110, 288-98	9.7	33
246	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3506-3506	2.2	2

245	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3507-3507	2.2	6
244	Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3547-3547	2.2	10
243	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3632-TPS3632	2.2	3
242	Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTACOLOR platform.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 575-575	2.2	4
241	Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3545-3545	2.2	
240	DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3584-3584	2.2	
239	Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. <i>BMC Cancer</i> , 2014 , 14, 106	4.8	14
238	Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3338-47	12.9	77
237	Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. <i>Clinical Cancer Research</i> , 2014 , 20, 265-272	12.9	27
236	The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. <i>Pharmacogenomics Journal</i> , 2014 , 14, 424-31	3.5	30
235	Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. <i>Pharmacogenomics</i> , 2014 , 15, 1043-52	2.6	15
234	Breast cancer risk, nightwork, and circadian clock gene polymorphisms. <i>Endocrine-Related Cancer</i> , 2014 , 21, 629-38	5.7	57
233	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. <i>Clinical Cancer Research</i> , 2014 , 20, 4499-4510	12.9	44
232	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1031-39	12.9	164
231	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 862-73	21.7	190
230	Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. <i>British Journal of Cancer</i> , 2014 , 110, 2728-37	8.7	18
229	Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?. <i>Journal of Translational Medicine</i> , 2014 , 12, 131	8.5	20
228	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. <i>European Journal of Cancer</i> , 2014 , 50, 1740-1746	7.5	65

227	Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. <i>Digestive and Liver Disease</i> , 2014 , 46, 97-104	3.3	180
226	The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. <i>Chest</i> , 2014 , 146, 633-643	5.3	70
225	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. <i>Journal of Cancer</i> , 2014 , 5, 425-32	4.5	28
224	MicroRNA related polymorphisms and breast cancer risk. <i>PLoS ONE</i> , 2014 , 9, e109973	3.7	37
223	Comment on KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer <i>British Journal of Cancer</i> , 2014 , 111, 2379-80	8.7	3
222	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. <i>PLoS Genetics</i> , 2014 , 10, e1004285	6	38
221	Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluorouracil chemotherapy. <i>Pharmacogenomics Journal</i> , 2014 , 14, 135-41	3.5	10
220	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , 2014 , 25, 2378-2385	10.3	72
219	Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. <i>British Journal of Cancer</i> , 2014 , 110, 1148-54	8.7	43
218	Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel 2014 ,		4
217	Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3511-3511	2.2	26
216	Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3523-3523	2.2	2
215	Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National AcsProgram.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS2647-TPS2647	2.2	2
214	Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. <i>PLoS ONE</i> , 2014 , 9, e103159	3.7	86
213	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3549-3549	2.2	
212	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 205-205	2.2	
211	Microsatellite instability analysis in uterine cavity washings to detect endometrial cancer in Lynch syndrome. <i>Anticancer Research</i> , 2014 , 34, 3211-5	2.3	
210	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. <i>International Journal of Cancer</i> , 2013 , 133, 1259-65	7.5	141

209	Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. <i>Clinical Chemistry</i> , 2013 , 59, 1722-31	5.5	377
208	CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. <i>Journal of Medical Genetics</i> , 2013 , 50, 486-9	5.8	105
207	Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. <i>Annals of Oncology</i> , 2013 , 24, 2624-2629	10.3	62
206	Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. <i>European Journal of Cancer</i> , 2013 , 49, 2531-41	7.5	29
205	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013 , 93, 1046-60	11	80
204	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. <i>BMC Cancer</i> , 2013 , 13, 472	4.8	10
203	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
202	Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. <i>Annals of Oncology</i> , 2013 , 24, 412-419	10.3	67
201	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. <i>American Journal of Human Genetics</i> , 2013 , 92, 489-503	11	167
200	The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. <i>European Journal of Cancer</i> , 2013 , 49, 2126-33	7.5	16
199	Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. <i>Clinical Chemistry</i> , 2013 , 59, 815-23	5.5	78
198	Colon cancer mutation: prognosis/prediction--letter. <i>Clinical Cancer Research</i> , 2013 , 19, 1300	12.9	3
197	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013 , 45, 392-8, 398e1-2	36.3	327
196	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013 , 45, 353-61, 361e1-2	36.3	813
195	Prediction of Chemotherapy Toxicities 2013 , 249-273		
194	A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. <i>Gastroenterology</i> , 2013 , 145, 176-187	13.3	254
193	Therapeutic implications of DNA mismatch repair in adjuvant colorectal cancer chemotherapy. <i>Colorectal Cancer</i> , 2013 , 2, 51-59	0.8	1
192	Surgery: Cetuximab--an option for unresectable CRC liver metastases. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 374-5	19.4	1

191	Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. <i>PLoS Medicine</i> , 2013 , 10, e1001453	11.6	794
190	Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. <i>Mutagenesis</i> , 2013 , 28, 323-31	2.8	31
189	Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. <i>International Journal of Cancer</i> , 2013 , 132, 2217-21	7.5	62
188	Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. <i>British Journal of Cancer</i> , 2013 , 109, 3057-66	8.7	74
187	Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. <i>PLoS ONE</i> , 2013 , 8, e68945	3.7	17
186	Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3562-3562	2.2	1
185	Gender specific profiling in SCN1A polymorphisms and time to recurrence in patients with stage II/III colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 393-393	2.2	
184	Microsatellite instability analysis for the screening of synchronous endometrial and ovarian cancer in Lynch syndrome. <i>Anticancer Research</i> , 2013 , 33, 3977-81	2.3	3
183	Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. <i>Experimental and Molecular Pathology</i> , 2012 , 92, 275-80	4.4	90
182	Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. <i>International Journal of Cancer</i> , 2012 , 130, 1367-77	7.5	16
181	DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma. <i>Tumor Biology</i> , 2012 , 33, 41-51	2.9	4
180	Biologie moléculaire et prise en charge des cancers colorectaux. <i>Oncologie</i> , 2012 , 14, 45-51	1	
179	9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1783-91	4	17
178	Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. <i>Journal of Hepatology</i> , 2012 , 56, 869-76	13.4	33
177	Detecting biomarkers with microdroplet technology. <i>Trends in Molecular Medicine</i> , 2012 , 18, 405-16	11.5	83
176	MicroRNA and colorectal cancer. <i>Digestive and Liver Disease</i> , 2012 , 44, 195-200	3.3	59
175	Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. <i>Lung Cancer</i> , 2012 , 76, 309-15	5.9	51
174	Potential Role of KRAS and Other Mutations in the Adjuvant Therapy of Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 192-203	1	

173	Dual blockade of epidermal growth factor receptor-induced pathways: a new avenue to treat metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1550-2	2.2	8
172	TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. <i>PLoS ONE</i> , 2012 , 7, e29954	3.7	51
171	O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial. <i>Annals of Oncology</i> , 2012 , 23, iv17	10.3	5
170	Association between Parkinson disease and the HLA-DRB1 locus. <i>Movement Disorders</i> , 2012 , 27, 1104-10	10	85
169	Prediction of response to anticancer treatment as simple as the resolution of ordinary differential equations?. <i>Gut</i> , 2012 , 61, 637-8	19.2	1
168	Clinicopathologic characteristics of endometrial cancer in Lynch syndrome.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5098-5098	2.2	
167	Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. <i>Lab on A Chip</i> , 2011 , 11, 2156-66	7.2	389
166	Microsatellite instability analysis in uterine cavity washings as a screening tool for endometrial cancer in Lynch syndrome. <i>Familial Cancer</i> , 2011 , 10, 655-7	3	2
165	Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 253-60	2.8	47
164	Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. <i>International Journal of Cancer</i> , 2011 , 128, 2591-601	7.5	82
163	Reply to S.D. Richman et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e356-e357	2.2	1
162	Reply to D. Santini et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e208-e209	2.2	4
161	External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. <i>Oncologist</i> , 2011 , 16, 467-78	5.7	75
160	Complex interplay between Eatenin signalling and Notch effectors in intestinal tumorigenesis. <i>Gut</i> , 2011 , 60, 166-76	19.2	97
159	Oncogenic mutations as predictive factors in colorectal cancer. <i>Oncogene</i> , 2010 , 29, 3033-43	9.2	87
158	Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. <i>Diabetes</i> , 2010 , 59, 1836-44	0.9	46
157	p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. <i>Lung Cancer</i> , 2010 , 67, 23-30	5.9	48
156	Down-regulation of the phosphoenolpyruvate carboxykinase gene in human colon tumors and induction by omega-3 fatty acids. <i>Biochimie</i> , 2010 , 92, 1772-7	4.6	9

155	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology, The</i> , 2010 , 11, 753-62	21.7	1653
154	Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2556-64 ²	2.2	127
153	Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. <i>International Journal of Cancer</i> , 2010 , 127, 1028-37	7.5	19
152	Microsatellite Status and Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 148-157	1	2
151	Circulating free tumor DNA and colorectal cancer. <i>Gastroenterologie Clinique Et Biologique</i> , 2010 , 34, 662-81		45
150	Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. <i>International Journal of Cancer</i> , 2010 , 127, 1321-31 ⁵	7.5	41
149	Analysis of candidate genes in occurrence and growth of colorectal adenomas. <i>Journal of Oncology</i> , 2009 , 2009, 306786	4.5	2
148	Mutations and response to epidermal growth factor receptor inhibitors. <i>Clinical Cancer Research</i> , 2009 , 15, 1133-9	12.9	107
147	No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer. <i>Molecular Carcinogenesis</i> , 2009 , 48, 581-5	5	11
146	Molecular predictors of response to EGFR antibodies in colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009 , 5, 57-63	1	1
145	Incidence of KRAS status in ongoing adjuvant trials in colon cancer. <i>Current Colorectal Cancer Reports</i> , 2009 , 5, 171-178	1	2
144	Genetics: Predictive value of KRAS mutations in chemoresistant CRC. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 306-7	19.4	26
143	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5068-74	2.2	284
142	Beyond the KRAS test. <i>European Journal of Cancer</i> , 2009 , 45 Suppl 1, 398-9	7.5	3
141	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5924-30	2.2	586
140	Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. <i>Personalized Medicine</i> , 2009 , 6, 145-157	2.2	2
139	Évaluation et validation des tests diagnostiques dans le cadre du ciblage thérapeutique. <i>Thérapie</i> , 2009 , 64, 187-194	3.8	5
138	Evaluation and validation of diagnostic tests for guiding therapeutic decisions. <i>Thérapie</i> , 2009 , 64, 187-201 ³	3.8	3

137	Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. <i>Anti-Cancer Drugs</i> , 2009 , 20, 932-40	2.4	11
136	Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2825-35; quiz 2836	0.7	101
135	A genetic study of the role of the Wnt/beta-catenin signalling in Paneth cell differentiation. <i>Developmental Biology</i> , 2008 , 324, 288-96	3.1	84
134	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. <i>Journal of Clinical Oncology</i> , 2008 , 26, 374-9	2.2	1240
133	The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. <i>Cancer Research</i> , 2008 , 68, 3907-14	10.1	57
132	Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 183-9	3.5	21
131	KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2228-30; author reply 2230-1	2.2	26
130	Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. <i>Cancer Research</i> , 2008 , 68, 8541-6	10.1	234
129	K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. <i>Clinical Cancer Research</i> , 2008 , 14, 4830-5	12.9	130
128	Hepatocellular carcinoma and occupation in men: a case-control study. <i>Journal of Occupational and Environmental Medicine</i> , 2008 , 50, 212-20	2	5
127	Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?. <i>Current Opinion in Oncology</i> , 2008 , 20, 454-8	4.2	14
126	Molecular predictors of response to EGFR antibodies in colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2008 , 4, 119-125	1	
125	Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. <i>BMC Medical Genomics</i> , 2008 , 1, 25	3.7	28
124	Mitochondrial D310 mutations in colorectal adenomas: an early but not causative genetic event during colorectal carcinogenesis. <i>International Journal of Cancer</i> , 2008 , 122, 2242-8	7.5	16
123	Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. <i>International Journal of Cancer</i> , 2008 , 122, 2255-9	7.5	237
122	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. <i>Hepatology</i> , 2007 , 45, 42-52	11.2	805
121	UDP-glucuronosyltransferase UGT1A7 genetic polymorphisms in hepatocellular carcinoma: a differential impact according to seropositivity of HBV or HCV markers?. <i>BMC Cancer</i> , 2007 , 7, 214	4.8	20
120	UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. <i>Clinical Cancer Research</i> , 2007 , 13, 3269-75	12.9	115

119	Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study. <i>Familial Cancer</i> , 2007 , 6, 295-9	3	21
118	Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. <i>Cancer Research</i> , 2007 , 67, 2611-6	10.1	53
117	Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. <i>Pharmacogenomics</i> , 2007 , 8, 997-1003	2.6	31
116	Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. <i>BMC Cancer</i> , 2006 , 6, 270	4.8	45
115	Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. <i>Hepatology</i> , 2006 , 43, 515-24	11.2	612
114	Identification of the IFITM family as a new molecular marker in human colorectal tumors. <i>Cancer Research</i> , 2006 , 66, 1949-55	10.1	104
113	Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. <i>Clinical Cancer Research</i> , 2006 , 12, 3050-6	12.9	176
112	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. <i>Cancer Research</i> , 2006 , 66, 3992-5	10.1	1852
111	Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 1309-15	6.7	77
110	Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. <i>British Journal of Cancer</i> , 2006 , 94, 692-7	8.7	52
109	Genetics of hepatocellular tumors. <i>Oncogene</i> , 2006 , 25, 3778-86	9.2	275
108	Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 897-902	6.9	106
107	Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. <i>Gastroenterology</i> , 2005 , 128, 1211-8	13.3	174
106	Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. <i>Blood</i> , 2005 , 106, 135-40	2.2	301
105	Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. <i>Oncogene</i> , 2005 , 24, 7253-6	9.2	32
104	Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. <i>American Journal of Transplantation</i> , 2005 , 5, 595-603	8.7	116
103	Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. <i>Human Molecular Genetics</i> , 2005 , 14, 603-14	5.6	90
102	Clinical value of mitochondrial mutations in colorectal cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3517-25	12.6	126

101	An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. <i>Gut</i> , 2005 , 54, 169	19.2	10
100	Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine. <i>Development (Cambridge)</i> , 2005 , 132, 1443-51	6.6	227
99	Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 594-9	12.9	40
98	Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. <i>Clinical Cancer Research</i> , 2004 , 10, 5880-8	12.9	206
97	Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 2594-9	12.9	32
96	Mutation of TCF1 encoding hepatocyte nuclear factor 1alpha in gynecological cancer. <i>Oncogene</i> , 2004 , 23, 7588-92	9.2	20
95	Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. <i>British Journal of Cancer</i> , 2004 , 90, 526-34	8.7	78
94	Is the gene encoding Chibby implicated as a tumour suppressor in colorectal cancer?. <i>BMC Cancer</i> , 2004 , 4, 31	4.8	11
93	Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer. <i>International Journal of Cancer</i> , 2004 , 110, 183-7	7.5	19
92	Pharmacogenetics of acenocoumarol pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 403-14	6.1	42
91	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 422-33	6.1	150
90	Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. <i>Journal of Hepatology</i> , 2004 , 41, 292-8	13.4	108
89	Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. <i>Anticancer Research</i> , 2004 , 24, 2021-6	2.3	24
88	Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 1889-96	12.7	235
87	Myeloperoxidase. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 729-739		31
86	Genetic alterations in hepatocellular adenomas. <i>Hepatology</i> , 2003 , 37, 480; author reply 480-1	11.2	7
85	TP53 and head and neck neoplasms. <i>Human Mutation</i> , 2003 , 21, 252-7	4.7	63
84	Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. <i>Gastroenterology</i> , 2003 , 124, 1311-4	13.3	22

83	Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 247-57	59.2	1641
82	Prognostic value of P53 mutations in rectal carcinoma. <i>International Journal of Cancer</i> , 2002 , 100, 131-5	7.5	43
81	Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. <i>International Journal of Cancer</i> , 2002 , 100, 542-8	7.5	211
80	Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. <i>Oncogene</i> , 2002 , 21, 1225-32	9.2	57
79	Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2002 , 21, 5016-23	9.2	16
78	Bi-allelic inactivation of TCF1 in hepatic adenomas. <i>Nature Genetics</i> , 2002 , 32, 312-5	36.3	279
77	Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). <i>British Journal of Cancer</i> , 2002 , 86, 1518-23	8.7	131
76	Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. <i>British Journal of Cancer</i> , 2002 , 87, 551-4	8.7	107
75	Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2832-43	2.2	160
74	Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas. <i>British Journal of Cancer</i> , 2002 , 87, 400-4	8.7	37
73	Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. <i>International Journal of Cancer</i> , 2001 , 95, 162-7	7.5	35
72	Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2001 , 93, 725-30	7.5	46
71	Influence of cirrhosis on lamotrigine pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2001 , 51, 410-4	3.8	36
70	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. <i>Nature</i> , 2001 , 411, 599-603	50.4	4469
69	Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. <i>Carcinogenesis</i> , 2001 , 22, 1819-24	4.6	60
68	Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. <i>Gastroenterology</i> , 2001 , 120, 200-9	13.3	20
67	Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. <i>Gastroenterology</i> , 2001 , 120, 1763-73	13.3	483
66	Kirsten ras mutations in patients with colorectal cancer: the CASCAL II study. <i>British Journal of Cancer</i> , 2001 , 85, 692-6	8.7	701

65	Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. <i>FEBS Letters</i> , 2001 , 489, 59-66	3.8	51
64	Thymidylate synthase promoter polymorphism. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3442	2.2	16
63	p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1465-73	2.2	155
62	Association of a duodenal follicular lymphoma and hereditary nonpolyposis colorectal cancer. <i>Modern Pathology</i> , 2000 , 13, 586-90	9.8	16
61	Qualitative gene profiling: a novel tool in genomics and in pharmacogenomics that deciphers messenger RNA isoforms diversity. <i>Pharmacogenomics</i> , 2000 , 1, 187-97	2.6	20
60	Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. <i>British Journal of Cancer</i> , 2000 , 82, 913-23	8.7	63
59	Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. <i>Cancer Research</i> , 2000 , 60, 707-11	10.1	54
58	PCR-based genotyping can generate artifacts in LOH analyses. <i>BioTechniques</i> , 1999 , 27, 1100-2	2.5	12
57	Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. <i>Oncogene</i> , 1999 , 18, 4044-6	9.2	132
56	Deletion mapping of the tumor suppressor locus involved in colorectal cancer on chromosome band 8p21. <i>Genes Chromosomes and Cancer</i> , 1999 , 25, 147-53	5	23
55	Frequent allelic loss at chromosome 3p distinct from genetic alterations of the 8-oxoguanine DNA glycosylase 1 gene in head and neck cancer. <i>Molecular Carcinogenesis</i> , 1999 , 26, 254-260	5	46
54	Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. <i>International Journal of Cancer</i> , 1999 , 84, 150-4	7.5	83
53	No evidence for germline PTEN mutations in families with breast and brain tumours. <i>International Journal of Cancer</i> , 1999 , 84, 216-9	7.5	16
52	Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. <i>International Journal of Cancer</i> , 1999 , 84, 410-5	7.5	32
51	Frequent allelic loss at chromosome 3p distinct from genetic alterations of the 8-oxoguanine DNA glycosylase 1 gene in head and neck cancer 1999 , 26, 254		1
50	Somatically acquired genetic alterations in flat colorectal neoplasias. <i>International Journal of Cancer</i> , 1998 , 77, 366-9	7.5	30
49	Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. <i>Human Mutation</i> , 1998 , 12, 424-30	4.7	71
48	Association of serum antibodies against p53 protein with poor survival in patients with Zollinger-Ellison syndrome. <i>Gastroenterology</i> , 1998 , 114, 37-43	13.3	4

47	Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis. <i>Journal of Medical Genetics</i> , 1998 , 35, 218-21	5.8	49
46	APC gene: database of germline and somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1998 , 26, 269-70	20.1	113
45	Alternative genetic pathways in colorectal carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 12122-7	11.5	194
44	Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France. <i>International Journal of Cancer</i> , 1997 , 74, 614-9	7.5	26
43	Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. <i>Journal of Clinical Microbiology</i> , 1997 , 35, 1734-9	9.7	53
42	BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. <i>American Journal of Human Genetics</i> , 1997 , 60, 1021-30	11	91
41	A high hepatitis E virus seroprevalence among renal transplantation and haemophilia patient populations. <i>Journal of Hepatology</i> , 1996 , 24, 122-5	13.4	21
40	Mapping of a susceptibility locus for Crohn's disease on chromosome 16. <i>Nature</i> , 1996 , 379, 821-3	50.4	789
39	Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. <i>Gut</i> , 1995 , 36, 455-8	19.2	37
38	Hepatitis C virus genotyping by means of 5'UTR/core line probe assays and molecular analysis of untypeable samples. <i>Virus Research</i> , 1995 , 38, 137-57	6.4	123
37	High resolution genetic map of the adenomatous polyposis coli gene (APC) region. <i>American Journal of Medical Genetics Part A</i> , 1995 , 56, 413-9		14
36	Screening for germ-line mutations in the NF2 gene. <i>Genes Chromosomes and Cancer</i> , 1995 , 12, 117-27	5	110
35	Host and viral characteristics affecting the response to interferon therapy in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 1995 , 7, 335-40	2.2	5
34	Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. <i>Oncogene</i> , 1995 , 10, 599-601	9.2	58
33	The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995 , 80, 3223-3226	5.6	67
32	Polymerase chain reaction assay for the detection of <i>Helicobacter pylori</i> in gastric biopsy specimens: comparison with culture, rapid urease test, and histopathological tests. <i>Gut</i> , 1994 , 35, 905-8	19.2	65
31	Enhanced detection of antibodies to hepatitis C virus by use of a third-generation recombinant immunoblot assay. <i>Journal of Medical Virology</i> , 1994 , 43, 259-61	19.7	21
30	Linkage analyses of chromosome 6 loci, including HLA, in familial aggregations of Crohn disease. G.E.T.A.I.D. <i>American Journal of Medical Genetics Part A</i> , 1994 , 52, 207-13		39

29	Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment. <i>Journal of Hepatology</i> , 1994 , 21, 1152	13.4	5
28	Indeterminate third-generation recombinant immunoblot assay in hepatitis C virus infection. Group d'Etudes Moléculaires des Hépatites (GEMHEP). <i>Journal of Hepatology</i> , 1994 , 21, 133-4	13.4	9
27	TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. <i>Gastroenterology</i> , 1994 , 107, 1012-8	13.3	153
26	Association of p53 mutations with short survival in colorectal cancer. <i>Gastroenterology</i> , 1994 , 106, 42-8	13.3	323
25	Analysis of sera indeterminate by Ortho-HCV RIBA-2 by using three confirmatory assays for anti-hepatitis C virus antibody. <i>Journal of Clinical Microbiology</i> , 1994 , 32, 2071-5	9.7	8
24	Prevalence of hepatitis C virus RNA in suspected drug induced liver diseases. <i>Journal of Hepatology</i> , 1993 , 19, 487-9	13.4	5
23	Alleles of the APC gene: an attenuated form of familial polyposis. <i>Cell</i> , 1993 , 75, 951-7	56.2	545
22	Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. <i>Cell</i> , 1993 , 75, 959-68	56.2	269
21	Chromosome 12 alterations and c-Ki-ras mutations in colorectal tumors. <i>Cancer Genetics and Cytogenetics</i> , 1993 , 69, 161-2		5
20	Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. <i>Gastroenterology</i> , 1993 , 105, 22-30	13.3	90
19	Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome?. <i>Gastroenterology</i> , 1993 , 105, 579-82	13.3	69
18	Hepatitis C virus infection in pediatric liver transplantation. <i>Transplantation</i> , 1993 , 55, 795-8	1.8	19
17	Lipase amylase ratio in acute pancreatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1993 , 5, 361-366	2.2	6
16	Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. <i>Cancer Research</i> , 1993 , 53, 5872-6	10.1	132
15	Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. <i>Oncogene</i> , 1993 , 8, 2213-20	9.2	50
14	Germ-line mutations in the first 14 exons of the adenomatous polyposis coli (APC) gene. <i>American Journal of Human Genetics</i> , 1993 , 52, 273-9	11	99
13	Survival and acquired genetic alterations in colorectal cancer. <i>Gastroenterology</i> , 1992 , 102, 1136-1141	13.3	161
12	Frequent polymorphism in the 13th exon of the adenomatous polyposis coli gene. <i>Human Genetics</i> , 1992 , 90, 161-3	6.3	3

11	Increased p53 protein content of colorectal tumours correlates with poor survival. <i>British Journal of Cancer</i> , 1992 , 66, 758-64	8.7	130
10	Prevalence of anti-hepatitis C virus antibodies among patients with alcoholic liver disease, supplemented by 4-RIBA. <i>Digestive Diseases and Sciences</i> , 1992 , 37, 156-7	4	3
9	Detection by DGGE of a new polymorphism closely linked to the adenomatous polyposis coli region. <i>Human Genetics</i> , 1992 , 88, 658-60	6.3	6
8	Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma. <i>Hepatology</i> , 1992 , 16, 1171-1175	11.2	50
7	Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma 1992 , 16, 1171		3
6	Genetic characterization of the APC locus involved in familial adenomatous polyposis. <i>Gastroenterology</i> , 1991 , 101, 154-60	13.3	14
5	Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. <i>International Journal of Cancer</i> , 1991 , 49, 220-3	7.5	57
4	Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. <i>Human Genetics</i> , 1991 , 86, 369-70	6.3	36
3	Reliability of presymptomatic test for adenomatous polyposis coli. <i>Lancet, The</i> , 1991 , 337, 1171-1172	40	4
2	Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. <i>International Journal of Cancer</i> , 1990 , 45, 450-6	7.5	73
1	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2